Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPACITY 004: Pirfenidone in IPF
NCT00287716Phase 3Completed
- Sponsor
- Genentech
- Start
- Jul 2006
- Primary completion
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pirfenidone in idiopathic pulmonary fibrosis (IPF), sponsored by Genentech. Started Jul 2006; status: completed.
02
Drugs
pirfenidone
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT00287716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00287716.